| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 49829* | 2017 |
| Antiinflammatory therapy with canakinumab for atherosclerotic disease PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, ... New England journal of medicine 377 (12), 1119-1131, 2017 | 7751 | 2017 |
| From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I M Naghavi, P Libby, E Falk, SW Casscells, S Litovsky, J Rumberger, ... Circulation 108 (14), 1664-1672, 2003 | 4953 | 2003 |
| Biological, clinical and population relevance of 95 loci for blood lipids TM Teslovich, K Musunuru, AV Smith, AC Edmondson, IM Stylianou, ... Nature 466 (7307), 707-713, 2010 | 4034 | 2010 |
| Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial SE Nissen, SJ Nicholls, I Sipahi, P Libby, JS Raichlen, CM Ballantyne, ... Jama 295 (13), 1556-1565, 2006 | 3010 | 2006 |
| Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia DL Bhatt, PG Steg, M Miller, EA Brinton, TA Jacobson, SB Ketchum, ... New England Journal of Medicine 380 (1), 11-22, 2019 | 2872 | 2019 |
| Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association M Miller, NJ Stone, C Ballantyne, V Bittner, MH Criqui, HN Ginsberg, ... Circulation 123 (20), 2292-2333, 2011 | 2318 | 2011 |
| Effects of dalcetrapib in patients with a recent acute coronary syndrome GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, ... New England Journal of Medicine 367 (22), 2089-2099, 2012 | 2260 | 2012 |
| Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) PH Jones, MH Davidson, EA Stein, HE Bays, JM McKenney, E Miller, ... The American journal of cardiology 92 (2), 152-160, 2003 | 2190 | 2003 |
| Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities … SJ Hwang, CM Ballantyne, AR Sharrett, LC Smith, CE Davis, AM Gotto Jr, ... Circulation 96 (12), 4219-4225, 1997 | 1964 | 1997 |
| Efficacy and safety of evolocumab in reducing lipids and cardiovascular events MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ... New England Journal of Medicine 372 (16), 1500-1509, 2015 | 1672 | 2015 |
| The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study AM McNeill, WD Rosamond, CJ Girman, SH Golden, MI Schmidt, HE East, ... Diabetes care 28 (2), 385-390, 2005 | 1536 | 2005 |
| Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientific statement from the American Heart Association EL Miller, L Murray, L Richards, RD Zorowitz, T Bakas, P Clark, ... Stroke 41 (10), 2402-2448, 2010 | 1374* | 2010 |
| Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions: The … AR Sharrett, CM Ballantyne, SA Coady, G Heiss, PD Sorlie, D Catellier, ... Circulation 104 (10), 1108-1113, 2001 | 1299 | 2001 |
| Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study BB Duncan, MI Schmidt, JS Pankow, CM Ballantyne, D Couper, A Vigo, ... Diabetes 52 (7), 1799-1805, 2003 | 1278 | 2003 |
| Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study V Nambi, L Chambless, AR Folsom, M He, Y Hu, T Mosley, K Volcik, ... Journal of the American College of Cardiology 55 (15), 1600-1607, 2010 | 1223 | 2010 |
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo … PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ... The Lancet 390 (10105), 1833-1842, 2017 | 1169 | 2017 |
| Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association MA Hlatky, P Greenland, DK Arnett, CM Ballantyne, MH Criqui, ... Circulation 119 (17), 2408-2416, 2009 | 1131 | 2009 |
| Effect of two intensive statin regimens on progression of coronary disease SJ Nicholls, CM Ballantyne, PJ Barter, MJ Chapman, RM Erbel, P Libby, ... New England Journal of Medicine 365 (22), 2078-2087, 2011 | 1105 | 2011 |
| Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial SJ Nicholls, R Puri, T Anderson, CM Ballantyne, L Cho, JJP Kastelein, ... Jama 316 (22), 2373-2384, 2016 | 1100 | 2016 |
